Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sanbiozi Medical Science Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is handled by 1 distinct examiner, STANLEY, JARROD LEE. This individual is also the busiest examiner for the portfolio, with 1 pending office action currently under review.
The portfolio is situated within 1 distinct art unit. This concentration of the pending workload under a single examiner and art unit indicates a highly focused prosecution effort. The company can expect a consistent application of examination standards for this specific matter, as there are no other active cases to create conflicting requirements.
Working with 1 distinct examiner like STANLEY, JARROD LEE allows for a more personalized prosecution strategy. Practitioners can focus on the specific technical interpretations and procedural preferences of this individual. This streamlined structure minimizes the administrative burden often associated with managing a larger or more diverse set of pending applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STANLEY, JARROD LEE | 1 | — | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18917086 | METHOD OF TREATING VIRUS-ASSOCIATED INFECTION USING ACETAMINOPHEN | STANLEY, JARROD LEE | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18917086 | METHOD OF TREATING VIRUS-ASSOCIATED INFECTION USING ACETAMINOPHEN | STANLEY, JARROD LEE | 1629 | §101§102§112 | Non-Final OA | — | Pending | Oct 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanbiozi Medical Science Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jarrod Lee Stanley has the most, with 1 of Sanbiozi Medical Science Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
